1994
DOI: 10.1016/0165-5728(94)90238-0
|View full text |Cite
|
Sign up to set email alerts
|

Prostaglandins and inhibitors of arachidonate metabolism suppress experimental allergic encephalomyelitis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
24
0

Year Published

1997
1997
2013
2013

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 60 publications
(25 citation statements)
references
References 54 publications
1
24
0
Order By: Relevance
“…These results indicated that PGE 2 -EP4 signaling facilitates the EAE response, and thus, they provided genetic evidence in support of our previous data obtained with the EP4 antagonist ONO-AE3-208 in EAE (22). However, the fact that none of the other receptordeficient mouse lines showed an exaggerated EAE response did not provide a clue as to the presumed protective action of PGs in EAE suggested by previous studies with COX inhibitors (15)(16)(17)(18)(19)(20). Given that it was unclear from these experiments whether EP4 signaling functions other than during the immunization phase, we administered ONO-AE3-208 to C57BL/6 mice at a final dose of 10 mg/kg body mass per day in drinking water.…”
Section: Resultssupporting
confidence: 76%
See 1 more Smart Citation
“…These results indicated that PGE 2 -EP4 signaling facilitates the EAE response, and thus, they provided genetic evidence in support of our previous data obtained with the EP4 antagonist ONO-AE3-208 in EAE (22). However, the fact that none of the other receptordeficient mouse lines showed an exaggerated EAE response did not provide a clue as to the presumed protective action of PGs in EAE suggested by previous studies with COX inhibitors (15)(16)(17)(18)(19)(20). Given that it was unclear from these experiments whether EP4 signaling functions other than during the immunization phase, we administered ONO-AE3-208 to C57BL/6 mice at a final dose of 10 mg/kg body mass per day in drinking water.…”
Section: Resultssupporting
confidence: 76%
“…Given their antiinflammatory actions, COX inhibitors have been examined for their effects on EAE in many studies. However, these drugs have been shown to exacerbate or ameliorate the disease (15)(16)(17)(18)(19)(20), leaving the role of PGs an enigma. Prophylactic use of these drugs-that is, their administration beginning the day of immunization or beforeseems to suppress EAE symptoms, whereas their therapeutic administration after or immediately before disease onset has only a mildly suppressant or an aggravating effect.…”
mentioning
confidence: 99%
“…One group of rats (Aln) was given indomethacine (water-soluble salt, from Chiesi Farmaceutici, Parma, Italy) at a dose of 1.5 mg/kg subcutaneous (s.c.) twice daily. This dose was reported not to cause malaise or weight loss in female Lewis rats [5], and was lower than the threshold dose that causes gastrointestinal lesions in rats after several days of treatment [6]. Another group of rats (Alb) was given ibuprofen (lysine salt; from Lisapharma, Erba CO, Italy) at a dose of 25 mg/kg s.c. twice daily.…”
Section: Animals and Treatmentsmentioning
confidence: 99%
“…In particular, several studies have highlighted the role of PGE 2 and PGD 2 in the pathogenesis of EAE. For example, PGE 2 possesses vasoactive properties and has been directly and indirectly shown to modify EAE [17,51,72]. PGD 2 , the most abundant prostanoid in the CNS, has been implicated in the attenuation of inflammation and, more specifically, the regulation of microglia-astrocyte interactions and the control of demyelination, thereby providing a neuroprotective role [73][74][75].…”
Section: Discussionmentioning
confidence: 99%
“…For example, we and others have found that PGs, their precursors or compounds that alter prostanoid production had no effect or detrimental actions on the course of EAE [13,14]. In contrast, a long-acting analogue of PGE 1 and the PG synthesis inhibitor indomethacin, administered either singly or in combination, and the reversible PG inhibitor, piroxicam, reportedly suppressed EAE [15][16][17]. Furthermore, early reports indicated some neurological improvement in MS patients following long-term dietary intake of PG precursor polyunsaturated fatty acids which were also shown to be effective in models of EAE [18][19][20][21].…”
mentioning
confidence: 99%